Altimmune Inc's shares rose by 19.94% in pre-market trading, reaching a 5-day high, as the company announced significant news regarding its drug pemvidutide.
The surge is attributed to Altimmune receiving FDA Breakthrough Therapy Designation for pemvidutide, based on promising Phase 2b trial results that demonstrated significant improvements in treating metabolic dysfunction-associated steatohepatitis (MASH). This designation is expected to enhance the company's market position and drive future growth, reflecting strong investor optimism.
This breakthrough not only positions Altimmune favorably in the biopharmaceutical sector but also indicates a commitment to addressing critical patient needs, potentially leading to long-term value creation for shareholders.
Wall Street analysts forecast ALT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALT is 13.00 USD with a low forecast of 12.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast ALT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALT is 13.00 USD with a low forecast of 12.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 5.100
Low
12.00
Averages
13.00
High
14.00
Current: 5.100
Low
12.00
Averages
13.00
High
14.00
Barclays
NULL -> Overweight
initiated
$20
2026-01-27
New
Reason
Barclays
Price Target
$20
AI Analysis
2026-01-27
New
initiated
NULL -> Overweight
Reason
Barclays initiated coverage of Altimmune with an Overweight rating and $20 price target.
Barclays
NULL -> Overweight
initiated
$20
2026-01-27
New
Reason
Barclays
Price Target
$20
2026-01-27
New
initiated
NULL -> Overweight
Reason
Barclays initiated coverage of Altimmune with an Overweight rating and $20 price target. Barclays initiated coverage of 12 biotech stocks and assumed coverage of 11 with a positive view of the industry. The analyst likes the setup for the group in 2026. Many biotech stocks remain undervalued, the analyst tells investors in a research note. The firm expects continued mergers and acquisitions, "strong" underlying fundamentals, and less of a focus on drug pricing to act as "significant tailwinds."
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ALT
Unlock Now
Citizens JMP
Jonathan Wolleben
Outperform
to
Outperform
downgrade
$15 -> $14
2025-11-07
Reason
Citizens JMP
Jonathan Wolleben
Price Target
$15 -> $14
2025-11-07
downgrade
Outperform
to
Outperform
Reason
Citizens JMP analyst Jonathan Wolleben lowered the firm's price target on Altimmune to $14 from $15 and keeps an Outperform rating on the shares. The firm says it looks forward to the oral late-breaking presentation of pemvidutide's Phase 2b data at the Liver Meeting with 48-week data on track for this quarter.
UBS
Buy
downgrade
$26 -> $24
2025-08-13
Reason
UBS
Price Target
$26 -> $24
2025-08-13
downgrade
Buy
Reason
UBS lowered the firm's price target on Altimmune to $24 from $26 and keeps a Buy rating on the shares. Despite the IMPACT Phase 2b trial setback, UBS still sees a sizeable opportunity for pemvidutide in nonalcoholic steatohepatitis, the analyst tells investors in a research note.
About ALT
Altimmune, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing next-generation peptide-based therapeutics. It is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, metabolic dysfunction-associated steatohepatitis (MASH) and other indications. Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. Glucagon is also recognized as having direct effects on hepatic fat metabolism, to rapid reductions in levels of liver fat and serum lipids. The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. The Company also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
